Teresa Macarulla
特蕾莎·马卡鲁拉
MD, PhD
Senior Consultant Oncologist; Head, Pancreatic and Biliary Tract Cancer Unit高级肿瘤科顾问；胰腺及胆道肿瘤科主任
👥Biography 个人简介
Teresa Macarulla, MD, PhD is a senior oncologist at Vall d'Hebron University Hospital and a leading European expert in gastrointestinal and biliary tract malignancies. She has been a principal or co-investigator in numerous pivotal trials establishing new standards of care for biliary tract and pancreatic cancers, including studies of FGFR inhibitors in cholangiocarcinoma and nanoliposomal irinotecan combinations in PDAC. Her clinical research has contributed to multiple regulatory approvals across Europe and the United States, and she is recognized for bridging translational science with rigorous clinical trial design.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FGFR Inhibitor Trials in Cholangiocarcinoma
Key investigator in pivotal pemigatinib and futibatinib trials for FGFR2-altered biliary tract cancers, contributing to international enrollment and translational analyses that supported FDA and EMA approvals.
Nanoliposomal Irinotecan in PDAC
Participated in NAPOLI-1 and follow-on studies establishing nal-IRI plus fluorouracil/leucovorin as a standard second-line option for gemcitabine-refractory metastatic pancreatic cancer.
Gallbladder Cancer Systemic Therapy
Led investigator-initiated studies and participated in international collaborations to define optimal first- and second-line chemotherapy strategies and evaluate novel targeted agents in gallbladder cancer.
Representative Works 代表性著作
Pemigatinib for Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma: A Multicentre, Open-Label, Phase 2 Study
The Lancet Oncology (2020)
FIGHT-202 trial demonstrating durable responses to pemigatinib in FGFR2 fusion/rearrangement-positive CCA, leading to FDA accelerated approval.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
New England Journal of Medicine (2022)
FOENIX-CCA2 phase II trial establishing futibatinib as an effective covalent FGFR inhibitor in previously treated CCA with FGFR2 rearrangements.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 特蕾莎·马卡鲁拉 的研究动态
Follow Teresa Macarulla's research updates
留下邮箱，当我们发布与 Teresa Macarulla（Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment